173 related articles for article (PubMed ID: 28186993)
1. Therapeutically blocking Interleukin-11 Receptor-α enhances doxorubicin cytotoxicity in high grade type I endometrioid tumours.
Winship A; Van Sinderen M; Rainczuk K; Dimitriadis E
Oncotarget; 2017 Apr; 8(14):22716-22729. PubMed ID: 28186993
[TBL] [Abstract][Full Text] [Related]
2. Targeting Interleukin-11 Receptor-α Impairs Human Endometrial Cancer Cell Proliferation and Invasion In Vitro and Reduces Tumor Growth and Metastasis In Vivo.
Winship AL; Van Sinderen M; Donoghue J; Rainczuk K; Dimitriadis E
Mol Cancer Ther; 2016 Apr; 15(4):720-30. PubMed ID: 26846819
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 11 is upregulated in uterine lavage and endometrial cancer cells in women with endometrial carcinoma.
Yap J; Salamonsen LA; Jobling T; Nicholls PK; Dimitriadis E
Reprod Biol Endocrinol; 2010 Jun; 8():63. PubMed ID: 20553623
[TBL] [Abstract][Full Text] [Related]
4. Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration.
Winship A; Van Sinderen M; Heffernan-Marks A; Dimitriadis E
Int J Oncol; 2017 Mar; 50(3):798-804. PubMed ID: 28098860
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 11 regulates endometrial cancer cell adhesion and migration via STAT3.
Lay V; Yap J; Sonderegger S; Dimitriadis E
Int J Oncol; 2012 Aug; 41(2):759-64. PubMed ID: 22614117
[TBL] [Abstract][Full Text] [Related]
6. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
[TBL] [Abstract][Full Text] [Related]
7. Autocrine Prolactin Stimulates Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to Chemotherapy.
Ding K; Yuan Y; Chong QY; Yang Y; Li R; Li X; Kong X; Qian P; Xiong Z; Pandey V; Ma L; Wu Z; Lobie PE; Zhu T
Endocrinology; 2017 Jun; 158(6):1595-1611. PubMed ID: 28204229
[TBL] [Abstract][Full Text] [Related]
8. Peiminine serves as an adriamycin chemosensitizer in gastric cancer by modulating the EGFR/FAK pathway.
Tang Q; Wang Y; Ma L; Ding M; Li T; Nie Y; Gu Z
Oncol Rep; 2018 Mar; 39(3):1299-1305. PubMed ID: 29328433
[TBL] [Abstract][Full Text] [Related]
9. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
[TBL] [Abstract][Full Text] [Related]
10. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
Byron SA; Loch DC; Pollock PM
Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
[TBL] [Abstract][Full Text] [Related]
12. Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer.
Liu X; Lu Y; Xu Y; Hou S; Huang J; Wang B; Zhao J; Xia S; Fan S; Yu X; Du Y; Hou L; Li Z; Ding Z; An S; Huang B; Li L; Tang J; Ju J; Guan H; Song B
Cancer Lett; 2019 Sep; 459():122-134. PubMed ID: 31173853
[TBL] [Abstract][Full Text] [Related]
13. The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer.
Chitcholtan K; Sykes PH; Evans JJ
J Transl Med; 2012 Mar; 10():38. PubMed ID: 22394685
[TBL] [Abstract][Full Text] [Related]
14. Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells.
Zhang Z; Lin G; Yan Y; Li X; Hu Y; Wang J; Yin B; Wu Y; Li Z; Yang XP
Oncogene; 2018 Jun; 37(25):3456-3470. PubMed ID: 29559745
[TBL] [Abstract][Full Text] [Related]
15.
Altwerger G; Bonazzoli E; Bellone S; Egawa-Takata T; Menderes G; Pettinella F; Bianchi A; Riccio F; Feinberg J; Zammataro L; Han C; Yadav G; Dugan K; Morneault A; Ponte JF; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Mol Cancer Ther; 2018 May; 17(5):1003-1011. PubMed ID: 29440294
[TBL] [Abstract][Full Text] [Related]
16. Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation.
Shi Z; Zhou Q; Gao S; Li W; Li X; Liu Z; Jin P; Jiang J
Life Sci; 2019 Jan; 217():70-80. PubMed ID: 30452972
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model.
Evans A; Jamieson SM; Liu DX; Wilson WR; Perry JK
Cancer Lett; 2016 Aug; 379(1):117-23. PubMed ID: 27241667
[TBL] [Abstract][Full Text] [Related]
18. TESTIN suppresses tumor growth and invasion via manipulating cell cycle progression in endometrial carcinoma.
Gu Z; Ding G; Liang K; Zhang H; Guo G; Zhang L; Cui J
Med Sci Monit; 2014 Jun; 20():980-7. PubMed ID: 24929083
[TBL] [Abstract][Full Text] [Related]
19. CircRNA hsa_circ_0002577 accelerates endometrial cancer progression through activating IGF1R/PI3K/Akt pathway.
Wang Y; Yin L; Sun X
J Exp Clin Cancer Res; 2020 Aug; 39(1):169. PubMed ID: 32847606
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
